Market Overview

UPDATE: Jefferies Lowers PT on Amarin on Continued ANCHOR Partnership Discussion

Share:
Related AMRN
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 4
Stocks to Watch for October 23, 2014
Amarin: Modeling Its Cash Balance Trajectory To 2017 (Seeking Alpha)

In a report published Friday, Jefferies analyst Thomas Wei reiterated a Buy rating on Amarin (NASDAQ: AMRN), but lowered the price target from $24.00 to $20.00.

In the report, Jefferies noted, “We remain focused on the FDA panel meeting in October for ANCHOR and the launch of ANCHOR in 1H14 as the key catalysts for AMRN shares. The company remains in negotiations for a pharma partnership for ANCHOR, but also discussed the merits of self-commercialization.”

Amarin closed on Thursday at $5.31.

Latest Ratings for AMRN

DateFirmActionFromTo
Feb 2015SunTrust Robinson HumphreyUpgradesNeutralBuy
Nov 2014CitigroupMaintainsNeutral
May 2014CitigroupDowngradesBuyNeutral

View More Analyst Ratings for AMRN
View the Latest Analyst Ratings

Posted-In: Jefferies Thomas WeiAnalyst Color Price Target Analyst Ratings

 

Related Articles (AMRN)

Around the Web, We're Loving...

Get Benzinga's Newsletters